Skip to main content
All lobbying filings

American Academy of Neurology

American Academy of Neurology filed a Q1 report for American Academy of Neurology on May 6, 2025.

Lobbying for American Academy of Neurology

As filed: AMERICAN ACADEMY OF NEUROLOGY for AMERICAN ACADEMY OF NEUROLOGY.

All filings by American Academy of Neurology · Everything American Academy of Neurology has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted May 6, 2025
Expenses
$250,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Minnesota

Official filing document

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

Resident Physician Shortage Reduction Act Conrad State 30 and Physician Access Reauthorization Act Resident Education Deferred Interest Act of 2021 Bringing Regulatory Advances into Neuroscience (BRAIN) Act  Safe Step Act Urging support for and the bolstering of the neurology workforce Urging reforms to proposed surprise billing regulations to align with congressional intent for payment disputes. Support for creating a Neuroscience Center of Excellence at FDA. Medical research funding related to NIH including the BRAIN Initiative, AHRQ, HEAL Initiative, and the Congressionally Directed Medical Research Programs at the Department of Defense. Support for funding for the Pediatric Subspecialty Loan Repayment Program Support for research related to Long COVID

Telehealth Modernization Act Empowering Medicare Seniors to Negotiate Drug Prices Act CONNECT for Health Act of 2021 Strengthening Medicare for Patients and Providers Act Improving Seniors Timely Access to Care Act Engagement with CMS regarding National Coverage Analysis (NCA) of monoclonal antibodies directed at amyloid beta plaque for the treatment of Alzheimers Disease. Support for a permanent expansion of telehealth in Medicare, including eliminating on originating site and geographic restrictions. Support for policies to address prescription drug costs, including supporting direct negotiation in Medicare, improving drug pricing transparency, and capping beneficiary out-of-pocket costs in Medicare Part D. Expressing concerns with Medicare physician payment Expressing concerns related to prior authorization

Support for increased funding for the VA Neurology Centers of Excellence, which include centers dedicated to Epilepsy, Multiple sclerosis, Headache, and Parkinsons disease. Support for the VA Medical and Prosthetic Research Program VA teleneurology and patient access to telehealth

-Safe Step Act -Issues related to step therapy reform

Support for creating a Neuroscience Center of Excellence at FDA. Medical research funding related to NIH including the BRAIN Initiative, AHRQ, HEAL Initiative, and the Congressionally Directed Medical Research Programs at the Department of Defense. Support for increased funding for the VA Neurology Centers of Excellence, which include centers dedicated to Epilepsy, Multiple sclerosis, Headache, and Parkinsons disease.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem